E N D
Supplemental Digital Content 1- Figure 1.Synergism achieved by combining HP-OVA with HIV-1 entry inhibitors for inhibition of infection by HIV-1IIIB (A-E), and HIV-1BaL (F-J). (A) HP-OVA and NB64; (B) HP-OVA and T20; (C) HP-OVA and C52L; (D) HP-OVA and NBD556; (E) HP-OVA and AMD3100; (F) HP-OVA and NB64; (G) HP-OVA and T20; (H) HP-OVA and C52L; (I) HP-OVA and NBD556; and (J) HP-OVA and Maraviroc. Inhibitory activity on p24 production was detected by ELISA. Each sample was tested in triplicate, and the data are presented as means ± SD.